Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, outlines the rationale of AFFIRM-AL (NCT04973137), a Phase III trial evaluating the efficacy and safety of birtamimab plus standard of care (SOC) compared to placebo plus SOC in patients with Mayo Stage IV AL amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.